^
Association details:
| Biomarker: | RET fusion |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC
Published date:
01/12/2021
Excerpt:
Lenvatinib resulted in a response rate of 16% and a median progression-free survival of 7.3 months among 25 patients with RET fusion-positive lung cancer.
Trial ID:
